Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 51

Sort by

Sort Order Select

Journal Articles

The Differences between Ide-Cel and Cilta-Cel in Relapsed Myeloma at Single Cell Resolution

Blood (2024) 144 (Supplement 1): 1877.

https://doi.org/10.1182/blood-2024-210746

Published: 2024

Journal Articles

Second-Line Bosutinib Is Effective and Feasible in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) - an Analysis of a Subcohort of the Bodo Trial (CML-VII-study of the German CML Study Group)

Blood (2024) 144 (Supplement 1): 1766.

https://doi.org/10.1182/blood-2024-208687

Published: 2024

Journal Articles

Measurable Residual Disease Detection of IDH1 or IDH2 Mutations Post but Not Prior to Allogeneic Hematopoietic Stem Cell Transplantation Show High Prognostic Relevance in Patients with Acute Myeloid Leukemia

Jacob Jendro, Lara Bischof, Jule Ussmann, Tung Pham Thanh, Donata Backhaus, Dominic Brauer, Vladan Vucinic, Carmen Herling, Marco Herling, Georg-Nikolaus Franke, Maximilian Merz, Klaus H Metzeler, Uwe Platzbecker, Sebastian Schwind, Madlen Jentzsch

Blood (2024) 144 (Supplement 1): 4334.

https://doi.org/10.1182/blood-2024-207490

Published: 2024

Journal Articles

Prognostic Value of Baseline and Early Response FDG-PET/CT Combined with Cellular Dynamics in Patients with Refractory and Relapsed Mantle Cell Lymphoma (MCL) Undergoing Chimeric Antigen Receptor (CAR)-T Cell Therapy

Blood (2024) 144 (Supplement 1): 6343.

https://doi.org/10.1182/blood-2024-206686

Published: 2024

Journal Articles

Single Vs. Tandem Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Real-World Multi-Center Study from the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)

Blood (2024) 144 (Supplement 1): 708.

https://doi.org/10.1182/blood-2024-198638

Published: 2024

Journal Articles

Impact of Allogeneic Hematopoietic Cell Transplantation Post-Sars-Cov-2 Infection: A Retrospective Analysis By the German Cooperative Transplant Study Group

Blood (2024) 144 (Supplement 1): 3554.

https://doi.org/10.1182/blood-2024-204560

Published: 2024

Journal Articles

Persistent Thrombocytopenia and Neutropenia Are Associated with Increased Mortality in Patients Treated with Anti-BCMA CAR T Cells for Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 7095.

https://doi.org/10.1182/blood-2024-202101

Published: 2024

Journal Articles

CT-Based Muscle Quality and Visceral Obesity Prior to Allogeneic Hematopoietic Stem Cell Transplantation Is of Prognostic Relevance in Patients with Acute Myeloid Leukemia

Jule Ussmann, Clara Wall, Lara Bischof, Jacob Jendro, Dominic Brauer, Donata Backhaus, Klaus H Metzeler, Marco Herling, Carmen Herling, Vladan Vucinic, Georg-Nikolaus Franke, Maximilian Merz, Timm Denecke, Uwe Platzbecker, Sebastian Schwind, Hans-Jonas Meyer, Madlen Jentzsch

Blood (2024) 144 (Supplement 1): 2158.

https://doi.org/10.1182/blood-2024-199943

Published: 2024

Journal Articles

Cellular Composition and Clinical Factors Influencing Manufacturing Outcomes for Anti-BCMA CAR T Cell Therapy in a Large Real-World Cohort of Relapsed/Refractory Multiple Myeloma

Vladan Vucinic, David Fandrei, Janine Kirchberg, Enrica Bach, Mandy Brueckner, Kathleen Friedrich, Carmen Herling, Madlen Jentzsch, Georg-Nikolaus Franke, Simone Heyn, Uwe Platzbecker, Maximilian Merz

Blood (2024) 144 (Supplement 1): 2094.

https://doi.org/10.1182/blood-2024-207117

Published: 2024

Journal Articles

Treatment Free Remission after Nilotinib Plus Peg-Interferon Alpha Induction and Peg-Interferon Alpha Maintenance Therapy for Newly Diagnosed Chronic Myeloid Leukemia Patients; The Tiger Trial

Blood (2023) 142 (Supplement 1): 446.

https://doi.org/10.1182/blood-2023-182792

Published: 2023

Journal Articles

Single Cell Multi-Omic Dissection of Response and Resistance to Chimeric Antigen Receptor T Cells Against BCMA in Relapsed Multiple Myeloma

Blood (2023) 142 (Supplement 1): 453.

https://doi.org/10.1182/blood-2023-187371

Published: 2023

Journal Articles

Apheresis for Production of Chimeric Antigen Receptor (CAR) T Cells in Patients with Multiple Myeloma - Clinical Factors, Cell Composition and T Cell Senescence

Vladan Vucinic, Janine Kirchberg, Mandy Brueckner, Patrick Born, Luise Fischer, Enrica Bach, Nora Grieb, Simone Heyn, Christina Kloetzer, Klaus H Metzeler, Sandra Hoffmann, Carmen Herling, Marco Herling, Georg-Nikolaus Franke, Sebastian Schwind, Song-Yau Wang, Madlen Jentzsch, Uwe Platzbecker, Maximilian Merz

Blood (2023) 142 (Supplement 1): 3521.

https://doi.org/10.1182/blood-2023-182222

Published: 2023

Journal Articles

Increased Bone Turnover and Decreased BCMA Levels in Patients with Response to Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma

Jule Ussmann, Luise Fischer, Patrick Born, Nora Grieb, Sandra Hoffmann, Ronny Baber, Song-Yau Wang, Christina Kloetzer, Simone Heyn, Marco Herling, Carmen Herling, Madlen Jentzsch, Georg-Nikolaus Franke, Lorenz Hofbauer, Uwe Platzbecker, Vladan Vucinic, Heike Weidner, Maximilian Merz

Blood (2023) 142 (Supplement 1): 6643.

https://doi.org/10.1182/blood-2023-185643

Published: 2023

Journal Articles

A Novel and Cost-Efficient Measurable Residual Disease (MRD) Detection Assay Using a Single Molecule Molecular Inversion Probe-Based Next Generation Sequencing (NGS) Assay Predicts Overall Survival in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation

Simon M. Krauß, Tara Holloway, Lara Bischof, Donata Backhaus, Dominic Brauer, Jule Ussmann, Anne Weigert, Georg-Nikolaus Franke, Vladan Vucinic, Uwe Platzbecker, Sebastian Schwind, Madlen Jentzsch, Klaus H Metzeler

Blood (2023) 142 (Supplement 1): 3616.

https://doi.org/10.1182/blood-2023-181728

Published: 2023

Journal Articles

Cellular Dynamics Following CAR T Cell Therapy Are Associated with Response, Resistance and Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma

Blood (2023) 142 (Supplement 1): 1008.

https://doi.org/10.1182/blood-2023-188367

Published: 2023

Journal Articles

Collections of Autologous Lymphocytes for Treatment with Chimeric Antigen Receptor (CAR) T-Lymphocytes - No Association of Clonal Hematopoiesis (CH) with Manufacturing Success

Blood (2022) 140 (Supplement 1): 7560–7562.

https://doi.org/10.1182/blood-2022-163360

Published: 2022

Journal Articles

Outcomes of Patients with Acute Myeloid Leukemia Receiving a Second Allogeneic Stem Cell Transplantation

Jule Ussmann, Lara Bischof, Dominic Brauer, Donata Backhaus, Marco Herling, Klaus H. Metzeler, Maximilian Merz, Vladan Vucinic, Georg-Nikolaus Franke, Uwe Platzbecker, Sebastian Schwind, Madlen Jentzsch

Blood (2022) 140 (Supplement 1): 4819–4820.

https://doi.org/10.1182/blood-2022-169268

Published: 2022

Journal Articles

Quantitative Impact of Mutated NPM1 MRD in Patients with AML Undergoing Allogeneic Stem Cell Transplantation

Sebastian Schwind, Lara Bischof, Marius Bill, Juliane Grimm, Jule Ussmann, Elizabeth Gaston, Donata Backhaus, Dominic Brauer, Marco Herling, Maximilian Merz, Klaus H. Metzeler, Georg-Nikolaus Franke, Vladan Vucinic, Uwe Platzbecker, Madlen Jentzsch

Blood (2022) 140 (Supplement 1): 3412–3413.

https://doi.org/10.1182/blood-2022-163365

Published: 2022

Journal Articles

Single-Cell Multi-Omics of Peripheral Blood Reveals Tiding and Evolution of Responsive and Resistant Clones upon Daratumumab-Based Treatments in Multiple Myeloma and Plasma Cell Leukemia

Blood (2022) 140 (Supplement 1): 4207–4208.

https://doi.org/10.1182/blood-2022-166241

Published: 2022

Journal Articles

Prognostic Impact of Measurable Residual Clonal Hematopoiesis after Allogeneic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia

Lara Bischof, Elizabeth Gaston, Jule Ussmann, Juliane Grimm, Marius Bill, Dominic Brauer, Donata Backhaus, Lisa Herrmann, Maximilian Merz, Marco Herling, Klaus H. Metzeler, Georg-Nikolaus Franke, Vladan Vucinic, Uwe Platzbecker, Sebastian Schwind, Madlen Jentzsch

Blood (2022) 140 (Supplement 1): 7750–7751.

https://doi.org/10.1182/blood-2022-169478

Published: 2022

NARROW

The Differences between Ide-Cel and Cilta-Cel in Relapsed Myeloma at Single Cell Resolution

Second-Line Bosutinib Is Effective and Feasible in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) - an Analysis of a Subcohort of the Bodo Trial (CML-VII-study of the German CML Study Group)

Measurable Residual Disease Detection of IDH1 or IDH2 Mutations Post but Not Prior to Allogeneic Hematopoietic Stem Cell Transplantation Show High Prognostic Relevance in Patients with Acute Myeloid Leukemia

Prognostic Value of Baseline and Early Response FDG-PET/CT Combined with Cellular Dynamics in Patients with Refractory and Relapsed Mantle Cell Lymphoma (MCL) Undergoing Chimeric Antigen Receptor (CAR)-T Cell Therapy

Single Vs. Tandem Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Real-World Multi-Center Study from the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)

Impact of Allogeneic Hematopoietic Cell Transplantation Post-Sars-Cov-2 Infection: A Retrospective Analysis By the German Cooperative Transplant Study Group

Persistent Thrombocytopenia and Neutropenia Are Associated with Increased Mortality in Patients Treated with Anti-BCMA CAR T Cells for Relapsed/Refractory Multiple Myeloma

CT-Based Muscle Quality and Visceral Obesity Prior to Allogeneic Hematopoietic Stem Cell Transplantation Is of Prognostic Relevance in Patients with Acute Myeloid Leukemia

Cellular Composition and Clinical Factors Influencing Manufacturing Outcomes for Anti-BCMA CAR T Cell Therapy in a Large Real-World Cohort of Relapsed/Refractory Multiple Myeloma

Treatment Free Remission after Nilotinib Plus Peg-Interferon Alpha Induction and Peg-Interferon Alpha Maintenance Therapy for Newly Diagnosed Chronic Myeloid Leukemia Patients; The Tiger Trial

Single Cell Multi-Omic Dissection of Response and Resistance to Chimeric Antigen Receptor T Cells Against BCMA in Relapsed Multiple Myeloma

Apheresis for Production of Chimeric Antigen Receptor (CAR) T Cells in Patients with Multiple Myeloma - Clinical Factors, Cell Composition and T Cell Senescence

Increased Bone Turnover and Decreased BCMA Levels in Patients with Response to Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma

A Novel and Cost-Efficient Measurable Residual Disease (MRD) Detection Assay Using a Single Molecule Molecular Inversion Probe-Based Next Generation Sequencing (NGS) Assay Predicts Overall Survival in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation

Cellular Dynamics Following CAR T Cell Therapy Are Associated with Response, Resistance and Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma

Collections of Autologous Lymphocytes for Treatment with Chimeric Antigen Receptor (CAR) T-Lymphocytes - No Association of Clonal Hematopoiesis (CH) with Manufacturing Success

Outcomes of Patients with Acute Myeloid Leukemia Receiving a Second Allogeneic Stem Cell Transplantation

Quantitative Impact of Mutated NPM1 MRD in Patients with AML Undergoing Allogeneic Stem Cell Transplantation

Single-Cell Multi-Omics of Peripheral Blood Reveals Tiding and Evolution of Responsive and Resistant Clones upon Daratumumab-Based Treatments in Multiple Myeloma and Plasma Cell Leukemia

Prognostic Impact of Measurable Residual Clonal Hematopoiesis after Allogeneic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only